Tarsus Pharmaceuticals to Showcase Innovations at Upcoming Event
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is gearing up to take an integral role at the BTIG 5th Annual Ophthalmology Day, scheduled for early next month. The management team will participate in a fireside chat on December 1st at 10:45 a.m. PT / 1:45 p.m. ET, aiming to connect with investors and share insights into their innovative journey in eye care and beyond.
What to Expect from the Conference
This conference will serve as a platform for Tarsus to discuss their cutting-edge research and development efforts, particularly in ophthalmology, where they aim to revolutionize treatment solutions for patients. Attendees can look forward to an engaging session that will delve into ongoing projects and future aspirations. A live webcast of the event will be available, allowing interested parties to participate and learn more about Tarsus’s pioneering work.
Tarsus's Commitment to Eye Care
At the heart of Tarsus’s mission is a dedication to applying proven science and state-of-the-art technology to improve patient outcomes in eye care. Their flagship product, XDEMVY (lotilaner ophthalmic solution) 0.25%, has already received FDA approval for treating Demodex blepharitis, showcasing the company’s innovative approach to tackling unmet medical needs.
Expanding Therapeutic Horizons
In addition to their advancements in eye care, Tarsus Pharmaceuticals is working on several promising projects within dermatology and infectious disease prevention. The company is actively developing TP-04 aimed at offering potential treatment options for ocular rosacea and TP-05, which is an oral tablet aimed at preventing Lyme disease, both currently in Phase 2 clinical trials.
Connecting with the Community
Through their participation in significant events like the BTIG Ophthalmology Day, Tarsus seeks to foster connections with investors and stakeholders who are passionate about advancing health care technologies. The replay of the fireside chat will also be accessible on their website within 48 hours for those unable to attend live.
Contacting Tarsus Pharmaceuticals
For those interested in learning more about Tarsus or discussing collaborations and investments, the company has provided accessible contact points. Adrienne Kemp, Senior Director of Corporate Communications, along with David Nakasone, Head of Investor Relations, are available for inquiries. Interested parties can reach out through their corporate communications email or by phone for more information on the company’s initiatives and opportunities.
Frequently Asked Questions
What is Tarsus Pharmaceuticals known for?
Tarsus Pharmaceuticals specializes in innovative therapies in eye care and other medical fields, focusing on addressing unmet patient needs.
When will Tarsus participate in the BTIG conference?
Tarsus management will participate on December 1st at 10:45 a.m. PT / 1:45 p.m. ET.
What products does Tarsus currently offer?
Currently, Tarsus offers XDEMVY for treating Demodex blepharitis, along with developing TP-04 and TP-05 for other medical conditions.
How can I view the conference session?
A live webcast will be available during the conference, and a replay will be uploaded to the Tarsus website shortly after the event.
Who can I contact for more information about Tarsus Pharmaceuticals?
Adrienne Kemp and David Nakasone are key points of contact for queries related to corporate communications and investor relations, respectively.
